As Enanta Pharmaceuticals INC (ENTA) Market Valuation Declined, Shareholder Matarin Capital Management LLC Trimmed by $2.53 Billion Its Stake

October 11, 2018 - By Carolyn Hewitt

Investors sentiment decreased to 1.5 in Q2 2018. Its down 0.16, from 1.66 in 2018Q1. It dived, as 16 investors sold ENTA shares while 46 reduced holdings. 34 funds opened positions while 59 raised stakes. 14.64 million shares or 3.25% more from 14.18 million shares in 2018Q1 were reported. Hbk Invests Lp owns 20,600 shares. Glenmede Tru Na accumulated 0% or 41 shares. Moreover, American International Gp Inc has 0.01% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Armistice Limited Liability Com owns 124,000 shares. Price T Rowe Assocs Inc Md accumulated 855,491 shares. Parkside Fin Savings Bank And Tru owns 13 shares or 0% of their US portfolio. Dimensional Fund Advsr Lp has invested 0.03% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Farallon Mngmt Ltd Co holds 0.77% or 1.08 million shares. Millennium Ltd Liability Corp holds 0% of its portfolio in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) for 4,246 shares. Texas Permanent School Fund invested in 0.01% or 9,327 shares. Ativo Cap Ltd Company reported 15,029 shares. Public Employees Retirement System Of Ohio, a Ohio-based fund reported 19,575 shares. Thrivent For Lutherans reported 9,913 shares. Yorktown Mgmt And Company stated it has 0.17% in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA). Moreover, Wolverine Asset has 0.03% invested in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA).

Since April 16, 2018, it had 0 buys, and 9 sales for $11.52 million activity. Luly Jay R. also sold $4.38 million worth of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) on Thursday, July 5. Another trade for 15,000 shares valued at $1.81 million was made by MELLETT PAUL J on Monday, June 11.

Matarin Capital Management Llc decreased its stake in Enanta Pharmaceuticals Inc. (ENTA) by 9.76% based on its latest 2018Q2 regulatory filing with the SEC. Matarin Capital Management Llc sold 21,804 shares as the company’s stock declined 21.40% while stock markets rallied. The institutional investor held 201,703 shares of the health care company at the end of 2018Q2, valued at $23.38 billion, down from 223,507 at the end of the previous reported quarter. Matarin Capital Management Llc who had been investing in Enanta Pharmaceuticals Inc. for a number of months, seems to be less bullish one the $1.50 billion market cap company. The stock increased 1.16% or $0.89 during the last trading session, reaching $77.35. About 79,013 shares traded. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 110.33% since October 11, 2017 and is uptrending. It has outperformed by 94.71% the S&P500.

Matarin Capital Management Llc, which manages about $198.00M and $1382.93B US Long portfolio, upped its stake in 1St Source Corporation (NASDAQ:SRCE) by 2,983 shares to 85,232 shares, valued at $4.55B in 2018Q2, according to the filing. It also increased its holding in Selective Insurance Group Inc. (NASDAQ:SIGI) by 9,100 shares in the quarter, for a total of 136,341 shares, and has risen its stake in Zumiez Inc. (NASDAQ:ZUMZ).

Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on November, 19. They expect $1.21 earnings per share, down 34.95 % or $0.65 from last year’s $1.86 per share. ENTA’s profit will be $23.45M for 15.98 P/E if the $1.21 EPS becomes a reality. After $0.97 actual earnings per share reported by Enanta Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 24.74 % EPS growth.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Ratings Coverage

Among 2 analysts covering Enanta Pharmaceuticals (NASDAQ:ENTA), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Enanta Pharmaceuticals had 4 analyst reports since May 24, 2018 according to SRatingsIntel. The company was initiated on Thursday, June 7 by Oppenheimer. As per Wednesday, August 8, the company rating was downgraded by Oppenheimer.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: